Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
- PMID: 3720181
- DOI: 10.1038/clpt.1986.143
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
Abstract
Three models, linked in series, can be used to analyze combined pharmacokinetic (PK) and pharmacodynamic (PD) data arising from non--steady-state experiments. A PK model relates dose to plasma drug concentration (Cp); a link model relates Cp to drug concentration at the effect site (Ce); and a PD model relates Ce to drug effect (E). All three submodels can be stated parametrically. Recently the use of a nonparametric PD submodel has been proposed (CLIN PHARMACOL THER 1984;35:733-41). In this article we use an extended nonparametric approach that represents both the PK and PD models nonparametrically, but retains a parametric link model. Cp data from several PK models and E data from several PD models were simulated. After the addition of noise to both the Cp and E data, they were analyzed by both the parametric and extended nonparametric methods. The methods were compared by how well they estimated the PD model. To assess robustness, the effect of misspecification of the PK submodel on the goodness of estimation of both methods was also compared. In the absence of model misspecification, the parametric method usually estimates the PD model better than the nonparametric method. However, this difference in the performances diminishes and even reverses when the PK model is misspecified. Because one can rarely be certain that model misspecification is absent, the nonparametric approach may offer a distinct advantage for routine analysis of PK/PD data.
Similar articles
-
Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.Clin Pharmacol Ther. 1984 Jun;35(6):733-41. doi: 10.1038/clpt.1984.104. Clin Pharmacol Ther. 1984. PMID: 6329584
-
Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.Comput Appl Biosci. 1987 Nov;3(4):345-9. doi: 10.1093/bioinformatics/3.4.345. Comput Appl Biosci. 1987. PMID: 2898970
-
Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.Br J Clin Pharmacol. 1994 Nov;38(5):389-400. doi: 10.1111/j.1365-2125.1994.tb04372.x. Br J Clin Pharmacol. 1994. PMID: 7893578 Free PMC article.
-
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13. Int J Clin Pharmacol Ther. 1997. PMID: 9352388 Review.
-
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.Drug Metab Pharmacokinet. 2009;24(1):3-15. doi: 10.2133/dmpk.24.3. Drug Metab Pharmacokinet. 2009. PMID: 19252332 Review.
Cited by
-
Pharmacokinetic/pharmacodynamic modeling: what it is!J Pharmacokinet Biopharm. 1987 Oct;15(5):545-55. doi: 10.1007/BF01061762. J Pharmacokinet Biopharm. 1987. PMID: 3694497
-
A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.J Pharmacokinet Biopharm. 1991 Oct;19(5):537-52. doi: 10.1007/BF01062962. J Pharmacokinet Biopharm. 1991. PMID: 1783991
-
Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters.Clin Pharmacokinet. 1993 Jun;24(6):507-18. doi: 10.2165/00003088-199324060-00006. Clin Pharmacokinet. 1993. PMID: 8099862
-
Pharmacokinetics of non-intravenous formulations of fentanyl.Clin Pharmacokinet. 2013 Jan;52(1):23-36. doi: 10.1007/s40262-012-0016-7. Clin Pharmacokinet. 2013. PMID: 23100195 Review.
-
Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine.Br J Clin Pharmacol. 1988 Nov;26(5):557-62. doi: 10.1111/j.1365-2125.1988.tb05295.x. Br J Clin Pharmacol. 1988. PMID: 3207560 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous